TY - JOUR
T1 - Folic acid to prevent neural tube defects
T2 - A potential pharmacy initiative with public health implications
AU - Ryan, Melody
PY - 2004/10
Y1 - 2004/10
N2 - Purpose: This study (1) reviewed available data and recommendations regarding the prevention of neural tube defects (NTDs) through folic acid supplementation for the general population, women with previous NTD pregnancies, and women with epilepsy and (2) examined the potential role of pharmacy in the prevention of NTDs. Methods: Published clinical literature was identified through a review of articles abstracted from MEDLINE and International Pharmaceutical Abstracts. Search terms were folic acid, neural tube defect, spina bifida, myelomeningocele, anencephaly, epilepsy, clinical guidelines, and pregnancy. Clinically relevant information consistent with current guidelines was extracted. Results: Administration of 0.4 mg/day of folic acid to women of child-bearing age decreases rates of NTDs. In the general population, two types of NTD-reduction strategies have been employed: educational campaigns and food supply supplementation. Continued surveillance of NTD rates is needed to fully assess the effect of food supply supplementation in the US. Women with previous NTD pregnancies should consume 4 mg/day of folic acid during the month before and the month after conception. Public health interventions, including targeted educational materials and a national database to track subsequent pregnancies in women with previous NTD pregnancies, are needed. No evidence-based information about the effectiveness or dosing of folic acid supplements in women with epilepsy is available. Conclusions: Pharmacists have an important role to play in the education of other health care professionals and patients about periconceptual folic acid supplementation. However, pharmacists must first be prepared to fulfill this role. Significant research in special populations - to determine the best folic acid dose and the most effective educational strategies - should be undertaken in the future.
AB - Purpose: This study (1) reviewed available data and recommendations regarding the prevention of neural tube defects (NTDs) through folic acid supplementation for the general population, women with previous NTD pregnancies, and women with epilepsy and (2) examined the potential role of pharmacy in the prevention of NTDs. Methods: Published clinical literature was identified through a review of articles abstracted from MEDLINE and International Pharmaceutical Abstracts. Search terms were folic acid, neural tube defect, spina bifida, myelomeningocele, anencephaly, epilepsy, clinical guidelines, and pregnancy. Clinically relevant information consistent with current guidelines was extracted. Results: Administration of 0.4 mg/day of folic acid to women of child-bearing age decreases rates of NTDs. In the general population, two types of NTD-reduction strategies have been employed: educational campaigns and food supply supplementation. Continued surveillance of NTD rates is needed to fully assess the effect of food supply supplementation in the US. Women with previous NTD pregnancies should consume 4 mg/day of folic acid during the month before and the month after conception. Public health interventions, including targeted educational materials and a national database to track subsequent pregnancies in women with previous NTD pregnancies, are needed. No evidence-based information about the effectiveness or dosing of folic acid supplements in women with epilepsy is available. Conclusions: Pharmacists have an important role to play in the education of other health care professionals and patients about periconceptual folic acid supplementation. However, pharmacists must first be prepared to fulfill this role. Significant research in special populations - to determine the best folic acid dose and the most effective educational strategies - should be undertaken in the future.
KW - Folic acid
KW - Neural tube defects
UR - http://www.scopus.com/inward/record.url?scp=5444230594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5444230594&partnerID=8YFLogxK
U2 - 10.1177/001857870403901007
DO - 10.1177/001857870403901007
M3 - Review article
AN - SCOPUS:5444230594
SN - 0018-5787
VL - 39
SP - 962
EP - 969
JO - Hospital Pharmacy
JF - Hospital Pharmacy
IS - 10
ER -